• Contact us: 01476 247 007
    MHRA post-transition period informationMHRA post-transition period informationMHRA post-transition period informationMHRA post-transition period information
    • How can we help
      • Pharmacovigilance
        • National contact person for pharmacovigilance – post Brexit
        • Pharmacovigilance Standard Operating Procedure Audits
        • Post Marketing Pharmacovigilance Support
        • Clinical Trial Pharmacovigilance Support
        • EU QPPV Provision
        • Quality & Compliance
        • Risk Assessment and Management
        • Signal Detection and Management
      • Medical Writing
      • Patient Information
      • Regulatory
      • Market Authorisation Holding
    • Brexit
    • Our Partners
      • Marti Farm
      • Affiliates
      • Medilink
      • External Team
    • News
    • Get in touch
    • Filter by
    • Categories
    • Tags
    • Authors
    • Show all
    • All
    • Brexit Updates
    • Industry News
    • NCPP
    • Patient Information
    • PDS News
    • Pharmacovigilance
    • Risk Management
    • All
    • Aimovig
    • BioCity
    • brexit ready
    • Brexit updates
    • British Association for the Study of Headache
    • CGRP
    • chronic migraine
    • coronavirus
    • COVID-19
    • Deputy QPPV for Pharmacovigilance
    • EMA latest guidance
    • erenumab
    • EU MA
    • EU QPPV
    • EU QPPV for Pharmacovigilance
    • EU/EEA QPPV
    • European Marketing Authorisation Holders (MAH)
    • GCP inspections
    • Good Clinical Practice inspections
    • MAH Service
    • Marketing Authorisation Holders
    • medilink east midlands business awards
    • MHRA latest guidance
    • MHRA post-transition period information
    • National Contact Person for Pharmacovigilance (NCPP)
    • NICE agrees to look again at Novartis’ Aimovig for migraine prevention
    • Novartis
    • Outstanding Achievement Award
    • Periodic Safety Update Reports
    • Pharmaceutical administration services
    • pharmacovigilance
    • Pharmacovigilance (QPPV)
    • Pharmacovigilance (QPPV) provision post-Brexit
    • Post-Authorisation Safety Studies-protocols and final study reports
    • PSMF (pharmacovigilance system master file)
    • Pure Drug Safety
    • QPPV (Qualified Person for Pharmacovigilance)
    • QPPVs based in the UK
    • Quality and compliance
    • Regulatory services
    • remain compliant in the UK
    • Responsible Person for Eudravigilance in clinical trials
    • Risk Management Plans
    • severe migraine
    • summer intern
    • Sygnature Discovery
    • the transition period for Pharmacovigilance and Regulatory
    • UK and non-UK Individual Case Safety Reports
    • UK QPPV
    • All
    • bone
    • Liselle Barnsley
    3rd September 2020
    MHRA post-transition period information from Pure Drug Safety
    3rd September 2020

    MHRA post-transition period information

    On Monday 1 September 2020, the MHRA released an update to the guidance on pharmacovigilance post-transitional period and I am sure we all heard the emails […]
    Do you like it?
    Read more

    PLEASE NOTE OUR NEW PHONE NUMBER AS OF 1st JUNE 2021
    Call our team +44(0) 1476 247 007
    email info@puredrugsafety.com



    Sign up for our newsletter

    Pure Drug Safety Ltd

    Pure Drug Safety Ltd · 1 year ago
    @PureDrugSafety



    Many clients have already put their NCPP in place with us here at PDS and are ready for January 2022.

    Read more 👉 https://t.co/6mnM9Dzoma

    #NationalContactPerson #KnowledgeablePerson #ExperiencedQppv https://t.co/rS2W4PZbDv

    View on Twitter


    0

    0

    © 2019 - 2023 Pure Drug Safety.
    As of 1st June 2021 NEW OFFICE & REGISTERED ADDRESS: BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF, UK
    Pure Drug Safety Limited is a company registered in England and Wales. Registered Company Number 7702236. VAT Registered Number 117 966 288
    For our GDPR and Privacy Policy click here
    Designed by Gather Creative | Content managed by Tailored Marketing Solutions | Built + Hosted by GIGER MEDIA